In the News
Dec 8, 2021Medtech Insight
The MODULAR ATP clinical trial has begun to enroll patients to evaluate the safety, performance and effectiveness of Boston Scientific’s mCRM modular therapy system, which includes the Emblem MRI S-ICD and the Empower MPS leadless pacemaker.
*The EMPOWER MPS is an investigational device and limited by U.S. law to investigational use only. It is not available for sale. Some device references are for informational purposes only and are pending CE Mark. Not available in the European Economic Area.
Dec 6, 2021Security Magazine
The global medical device manufacturer has maintained operational continuity throughout the pandemic, using clear processes and procedures mixed with a healthy dose of care.
Nov 22, 2021Fast Company (sponsored)
Our innovative TheraSphere™ technology, which increases HCC liver cancer survival rates, may be an effective treatment for other tumors.
Nov 15, 2021FiercePharma
CIO and SVP of IT Jodi Euerle Eddy, recently named one of FiercePharma’s 2021 Fiercest Women in Life Sciences, reflects on her career and the opportunity to turn Boston Scientific’s digital transformation strategy into a competitive advantage.
Nov 12, 20219 News Sydney
Our CHAMPION AF clinical trial is studying whether the WATCHMAN FLX device can reduce the risk of stroke for more people suffering from AFib. Learn more about one patient enrolled in the trial in Sydney, Australia.